Ensitrelvir, marketed as Xocova, works by inhibiting viral replication and is designed as a 5-day oral protective regimen, ...
The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...
Among the patients studied with chronic cough post-COVID-19, 47.1% were newly diagnosed with asthma and 18.8% with obstructive pulmonary ventilation dysfunction. Post-COVID-19 chronic cough may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results